FEED-Cystic Fibrosis (FEED-CF)

Summary

The goal of this study is to determine the extent to which excess dietary sugars serve as a precipitating factor in glucose intolerance in adults with cystic fibrosis (CF), a population at especially high risk for a unique form of diabetes (CF-related diabetes, CFRD) and with standard-of-care dietary recommendations (high-calorie, high-fat) that conflict with recommendations for other forms of diabetes. This trial will investigate if the typical high-sugar, high-fat CF diet plays a role in diabetes risk and visceral fat accumulation in people with CF. A total of 30 participants will get a low-added sugar, high-fat diet and the other 30 will get a standard CF diet with no sugar restrictions. Participants will be randomized to the diet group they are assigned. All foods will be provided for 8 weeks.

Eligibility

Inclusion Criteria:

1. Confirmed CF diagnosis
2. Ages 18 years and older
3. Baseline estimated daily total added sugar intake \>16 tsp, as estimated from the Dietary Screener Questionnaire (DSQ).

Exclusion Criteria:

1. Nocturnal tube feeds
2. BMI \<18.5 kg/m2
3. Life expectancy \< 12 months
4. Confirmed diagnosis of CFRD
5. Screening OGTT showing fasting hyperglycemia (≥126 mg/dL)
6. Chronic steroid use
7. Current pregnancy or lactation
8. Inability/unwillingness to consume the majority of foods on the menu during the study period
9. MRI-incompatible metal that cannot be removed for testing
10. Uncontrolled exocrine pancreatic insufficiency/malabsorption
11. Clinically instability, defined as no changes in medical regimen (including medications and pulmonary exacerbations) for at least 21 days prior to study visit
12. Initiation of CFTR modulator within previous 8 weeks OR unstable changes in weight and lung function due to CFTR modulator use
13. Actively trying to gain or lose weight
14. Any food allergies or intolerances that cannot be accommodated
15. Any medical condition deemed by the a study physician or PI that may preclude completion of the study or interfere with primary end points.

Conditions3

Locations1 site

Browse More Trials